A carregar...

Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38

[Image: see text] DNA damage activates checkpoints to arrest cell cycle progression in S and G2 phases, thereby providing time for repair and recovery. The combination of DNA-damaging agents and inhibitors of CHK1 (CHK1i) is an emerging strategy for sensitizing cancer cells. CHK1i induce replication...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Pharmacol Transl Sci
Main Authors: Warren, Nicholas J. H., Donahue, Katelyn L., Eastman, Alan
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2019
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7088890/
https://ncbi.nlm.nih.gov/pubmed/32259055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.9b00001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!